Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension.
about
Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failureCost benefit of treating hypertension.An off-the-shelf help list: a comprehensive catalog of preference scores from published cost-utility analyses.The economics of primary prevention of cardiovascular disease - a systematic review of economic evaluationsFrom 4S to IDEAL: the health economics of the statin trials.Incorporation of future costs in health economic analysis publications: current situation and recommendations for the future.The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology.Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Cost-Effectiveness Analysis.The cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke: results from the Study on COgnition and Prognosis in the Elderly.Predicting productivity based on EQ-5D: an explorative study.The cost-effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub-study to the HOPE study.The economic evaluation of obesity interventions: its time has come.Ethical objections against including life-extension costs in cost-effectiveness analysis: a consistent approach.The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden.Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer.Inconsistencies in the "Societal Perspective" on Costs of the Panel on Cost-Effectiveness in Health and Medicine
P2860
Q28469116-3A7DF18C-8C39-4550-A321-E4C76550C375Q33697759-651FD182-3531-4156-953B-587B7E7B7FF4Q34320716-058D2463-67AE-490B-828F-E714D1CC7A79Q36821473-3BBC209C-2D3C-446B-ACCC-CD22B6446CF3Q37451199-67061C08-BB76-4DE2-87F9-C265C286BC87Q38367421-45CC7AEB-CF8F-40C3-AE17-2E49BCE72AF9Q38610648-933FAE20-C4E8-4333-8306-7989E0D2BB7DQ39069173-947311D4-57B7-4CE1-96A9-04DD772EACEFQ42652103-1AA8B7C1-E4FB-4344-B999-90F8EB3B299DQ43455325-443D4435-3481-4D84-BFD3-BCA7F0519CD3Q43636135-E412CA65-61A3-4F70-A13A-D1A573ABF403Q45291679-E9139BAF-8608-46FD-943B-C57985E894ADQ46624604-E191402A-1EB8-4949-9D6D-634255338FB2Q46856543-C1E3D702-28A0-44FD-BDE0-A29F74741371Q53139216-2BDE9BEE-F7BE-41DE-8592-BD62C69CB6EBQ57345444-B84FCF6A-79E2-46A4-80AE-3E924C99A55F
P2860
Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Incorporating future costs in ...... the treatment of hypertension.
@en
type
label
Incorporating future costs in ...... the treatment of hypertension.
@en
prefLabel
Incorporating future costs in ...... the treatment of hypertension.
@en
P2860
P1476
Incorporating future costs in ...... the treatment of hypertension.
@en
P2093
R M O'Conor
P2860
P304
P356
10.1177/0272989X9701700403
P577
1997-10-01T00:00:00Z